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ABSTRACT
In metastatic breast cancers, the acquisition of metastatic ability, which leads 
to clinically incurable disease and poor survival, has been associated with acquisition 
of epithelial-mesenchymal transition (EMT) program and self-renewing trait (CSCs) 
via activation of PI3K/AKT and IL6/JAK2/STAT3 signaling pathways. We found that 
TrkB is a key regulator of PI3K/AKT and JAK/STAT signal pathway-mediated tumor 
metastasis and EMT program. Here, we demonstrated that TrkB activates AKT by 
directly binding to c-Src, leading to increased proliferation. Also, TrkB increases 
Twist-1 and Twist-2 expression through activation of JAK2/STAT3 by inducing c-Src-
JAK2 complex formation. Furthermore, TrkB in the absence of c-Src binds directly to 
JAK2 and inhibits SOCS3-mediated JAK2 degradation, resulting in increased total JAK2 
and STAT3 levels, which subsequently leads to JAK2/STAT3 activation and Twist-1 
upregulation. Additionally, activation of the JAK2/STAT3 pathway via induction of IL-6 
secretion by TrkB enables induction of activation of the EMT program via induction 
of STAT3 nuclear translocation. These observations suggest that TrkB is a promising 
target for future intervention strategies to prevent tumor metastasis, EMT program 
and self-renewing trait in breast cancer.
INTRODUCTION
There are several discrete steps in the biological 
cascade of metastasis, loss of cellular adhesion, increased 
motility and invasiveness, entry and survival into circulation, 
exit into new tissue, and eventual colonization of a distant 
site [1, 2]. During cancer pathogenesis, a transdifferentiation 
program defined as epithelial–mesenchymal transition (EMT) 
is activated to acquire the ability to execute the multiple 
steps of the invasion-metastasis cascade [3–5]. Furthermore, 
certain epithelial cells that pass through an EMT acquire the 
self-renewing traits associated with normal tissue (SCs) and 
cancer stem cells (CSCs) [6, 7].
Metastatic breast cancers are more chemoresistant 
forms of breast cancer with expression of high levels of 
EMT markers and exhibit a CD44high/CD24low antigenic 
phenotype, which results in their having stem cell-like 
characteristics (CSCs). There is accumulating evidences of 
a role of PI3K/AKT and JAK/STAT3 signaling pathways 
in tumor metastasis and EMT. Activation of the PI3K/
AKT pathway, IL-6/JAK2/STAT3 pathway, and stem 
cell-like characteristics contribute to the poor outcomes 
of metastatic breast cancers [8, 9]. Moreover, activated 
JAK2/STAT3 increases AKT activation through the 
induction of AKT [10], while increased STAT3 and AKT 
activation leads to tumor development and EMT [11, 12].
Independent of these findings, TrkB, a member of the 
tropomyosin-related kinase (Trk) family of neurotrophin 
receptors, is critical to biological processes in the 
developing and mature nervous systems, including neuronal 
growth, differentiation, and survival [13]. Also, TrkB is 
overexpressed in various cancer types, including prostate 
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cancer [14], multiple myeloma [15], Wilms’ tumor [16], 
lung cancer [17], pancreatic cancer [18] and neuroblastoma 
[19], and is associated with poor prognosis [20, 21]. In 
addition, TrkB expression is important to the regulation of 
angiogenesis [22] and acts as a potent mediator of anoikis 
resistance in epithelial cells through AKT activation [23, 24]. 
However, the signaling mechanisms of TrkB-mediated 
PI3K/AKT activation have remained unclear. Thus, even 
though TrkB expression may play an important role in the 
tumorignicity of many tumors, it is currently unclear how 
TrkB regulate interactions between metastasis and EMT at 
the invasive front of the tumor. In this report, we identified 
a new network involved in tumor metastasis and EMT that 
regulates and coordinates with TrkB. Surprisingly, we found 
that TrkB is primarily present in human breast cancer and 
acts as a key regulator of the PI3K/AKT and JAK/STAT 
signal pathway-mediated tumor metastasis, EMT, and self-
renewing trait.
RESULTS
c-Src is required for TrkB-induced activation of 
the PI3K-AKT pathway
It is reported that ectopic TrkB expression in RIE-
1 cells suppresses anoikis through AKT activation [25]. 
However, the signaling mechanisms that activates PI3K/
AKT signaling pathway have remained unclear. In addition, 
c-Src appears to be important for multiple aspects of tumor 
progression, including proliferation, disruption of cell/cell 
contacts, migration, invasiveness, resistance to apoptosis, and 
angiogenesis [26]. c-Src is also known to activate PI3K/AKT 
and the MAP/extracellular signal-regulated kinase (ERK) 
kinase (MEK)/ERK cascades through both focal adhesion 
kinase (FAK)-dependent and FAK-independent pathways 
[27]. This raises the possibility that TrkB regulates tumor 
progression by activation of PI3K/AKT signaling pathway via 
regulation of c-Src. However, the correlation of TrkB and c-Src 
in breast cancer has remained unknown and none of these 
findings indicates a link between these two sets of phenomena.
We initially examined whether the elevated levels 
of TrkB associated with the increase in phosphorylation of 
TrkB. As shown in Figure 1A, a highly metastatic MDA-
MB-231 human breast cancer cell line expresses high level 
of TrkB and it is phosphorylated. Therefore, we investigated 
whether TrkB collaborated with c-Src in tumorigenicity 
of breast cancer. We found that pretreatment with K252a 
(an inhibitor of TrkC tyrosine kinases) and SU6656 (an 
inhibitor of c-Src tyrosine kinases) markedly reduced levels 
of phosphorylated AKT, as well as induction of cyclin D1, 
indicating that the PI3K/AKT pathway, and cyclin D1 act 
downstream of c-Src in MDA-MB-231 cells (Figure 1B). 
We also investigated whether the inhibition of c-Src kinase 
activity blocks the colony formation of MDA-MB-231 cells 
using SU6656. Upon addition of 5 μM SU6656, the colony 
formation of MDA-MB-231 cells was markedly suppressed 
as indicated by failure to form microscopic or macroscopic 
colonies in soft agar when scored after 16 days (Figure 1C).
These observations led us to speculate that TrkB might 
modulate expression or activation of c-Src. To determine 
whether TrkB contributes to regulation of c-Src in MAD-
MB-231 cells, we selected highly metastatic MDA-MB-231 
and Hs578T cells stably expressing the TrkB-shRNAs. TrkB-
shRNA partially suppressed the expression of endogenous 
TrkB (i.e., a 80% reduction) in MDA-MB-231 and Hs578T 
cells (Supplementary Figure 1A). We next examined the 
expression of Src in MDA-MB-231 control-shRNA or 
TrkB-shRNA cells. c-Src expression was not affected by 
the knockdown of TrkB in MDA-MB-231 cells, but c-Src 
phosphorylation levels were significantly decreased in 
MDA-MB-231 TrkB-shRNA cells, suggesting that TrkB 
activates c-Src in these cells (Figure 1D). We further 
examined whether TrkB expression regulates MEK1/2 
and AKT activation, as well as the induction of cyclin D1 
expression. Levels of phosphorylated (activated) MEK1/2 
and AKT as well as cyclin D1 expression were markedly 
reduced in MDA-MB-231 TrkB-shRNA cells relative 
to MDA-MB-231 control-shRNA cells (Figure 1E). 
These results suggest that TrkB affects proliferation of 
MDA-MB-231 cells through activation of c-Src.
To further investigate the induction of c-Src 
phosphorylation by TrkB, we examined whether TrkB 
directly interacts with c-Src in MDA-MB-231 cells. 
Interestingly, endogenous TrkB was able to interact with 
endogenous c-Src under physiological conditions (Figure 
1F). To confirm this finding in a transient transfection 
system, V5-tagged TrkB and HA-tagged c-Src were 
transfected into 293T cells. As shown in Figure 1G, TrkB 
interacted strongly with c-Src. To identify the functional 
domain of c-Src responsible for the interaction with TrkB, 
we used a series of c-Src deletion constructs. The c-Src 
mutant lacking the N-terminal domain (c-Src ΔKD2, 3), 
c-Src ΔC, c-Src ΔKD-1, and c-Src ΔKD-2 still interacted 
with TrkB. However, the deletion of amino acid residues 
275–360 a.a. (c-Src ΔKD-3) abrogated the TrkB interaction 
(Figure 1H). These results clearly indicate that the region 
including amino acids 275–360 of c-Src, which includes 
the tyrosine kinase domain, is required for TrkB interaction.
Therefore, we examined whether c-Src activation is 
involved in the TrkB-induced Mek1 and AKT activation as 
well as cyclin D1 expression. To test this notion, we selected 
MDA-MB-231 cells stably expressing the c-Src-shRNAs. As 
shown in Supplementary Figure 1B, knockdown of c-Src in 
MDA-MB-231 cells (MDA-MB-231 c-Src-shRNA cells) 
resulted in decreases in the expression of endogenous c-Src of 
over 60%. Moreover, TrkB-induced AKT activation and cyclin 
D1 expression were significantly reduced in c-Src-shRNA 
cells (Figure 1I), indicating that TrkB might be involved in 
tumorigenicity and metastasis of breast cancer through TrkB-
mediated activation of PI3K/AKT and Ras-MAPK pathways 
or upregulation of cyclin D1 expression. Taken together, our 
findings show that c-Src is essential for the ability of TrkB 
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to constitutively activate the Ras-MAPK and the PI3K-AKT 
pathways and to induce cyclin D1 overexpression.
TrkB-induced c-Src activation is involved in JAK2 
activation, but not with STAT3 activation
Activation of STAT3 is required for c-Src-mediated 
proliferation, survival and transformation [28–31], and 
also mediates resistance to trastuzumab [32]. Moreover, 
activated STAT3 leads to AKT activation [10] and 
upregulates Twist-1, an EMT-induced transcription factor 
[33, 34]. These observations led us to speculate that TrkB 
is involved in regulation of STAT3 activation and PI3K/
AKT signaling through activation of c-Src, and that it 
is functionally linked to regulation of Twist-1. To test 
the effect of TrkB and c-Src on STAT3 activation, we 
initially examined whether inhibition of c-Src activity 
in the Hs578T and MDA-MB-231 cells affected STAT3 
activation. We found that JAK2 and STAT3 activation, 
as well as Twist-1 expression were markedly decreased 
after treatment of Hs578T and MDA-MB-231 cells with 
SU6656. Interestingly, JAK2 expression was markedly 
decreased; whereas STAT3 expression was not affected by 
SU6656 treatment (Figure 2A). Moreover, the inhibition 
of JAK2 activation in Hs578T and MDA-MB-231 cells 
significantly reduced JAK and STAT3 phosphorylation 
and Twist-1 expression after treatment with the JAK2 
Figure 1: TrkB-mediated c-Src activation induces activation of the PI3K/AKT and Ras-MAPK pathway. A. Identification 
of TrkB expression and autophosphorylation in MDA-MB-231 cell lines. Cell extracts were immunoprecipitated using anti-TrkB antibody 
and Gamma-bind beads, after which they were immunoblotted with anti-phosphotyrosine antibody. B. Western blot analysis of expression 
of phospho-AKT and cyclin D1 in MDA-MB-231 cells treated with 50 nM K252a or 5 μM SU6656. β-actin was used as a loading control. 
C. Colony formation assay of MDA-MB-231 cells treated with 5 μM SU6656 (n = 3). *P < 0.001, t-test. D. Western blot analysis of 
expression of phospho-c-Src and c-Src in MDA-MB-231 control-shRNA or TrkB-shRNA cells. β-actin was used as a loading control. 
E. Western blot analysis of expression of phospho-AKT, phospho-MEK, and cyclin D1 in MDA-MB-231 control-shRNA or TrkB-shRNA 
cells. β-actin was used as a loading control. F. Identification of complex formation of endogenous TrkB/c-Src in MBA-MB-231 cells. 
G. TrkB interacts with the c-Src after transfection with c-Src or TrkB. H. Identification of the c-Src region responsible for TrkB interaction. 
Immunoblot analysis of whole-cell lysates and immunoprecipitates derived from 293T cells transfected with the V5-TrkB and Myc-c-Src 
deletion constructs was conducted as indicated. I. Western blot analysis of expression of phospho-c-Src, phospho-AKT, c-Src, AKT, and 
cyclin D1 in MDA-MB-231 control-shRNA or c-Src-shRNA cells. β-actin was used as a loading control.
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inhibitor, AG490. However, JAK2 and STAT3 expression 
levels were not significantly different after treatment 
with AG490 (Figure 2B). Our results suggest that c-Src 
activation is involved in the upregulation of JAK2, which 
is correlated with JAK2 phosphorylation, but not with 
STAT3 activation.
Given-mentioned role of TrkB as c-Src activator 
via direct interaction, it is possible that the TrkB/c-Src 
complex could activate JAK2 via interaction. Indeed, we 
found that both TrkB and c-Src interacted with JAK2 after 
transient transfection (Supplementary Figure 2A). Moreover, 
endogenous TrkB interacted with endogenous c-Src/JAK2 in 
MDA-MB-231 and Hs578T cells (Figure 2C). Furthermore, 
JAK2 interacted with TrkB even in the absence of c-Src 
or SU6656 treatment, indicating a direct binding of TrkB 
to JAK2 (Figures 2D and Supplementary Figure 2B). To 
identify the JAK2 functional domain responsible for its 
interaction with TrkB, we used a series of JAK2 deletion 
Figure 2: TrkB led to Twist-1 upregulation through activation of the JAK/STAT3 pathway after TrkB/c-Src/JAK2 
complex formation. A. Western blot analysis of expression of phospho-JAK2, JAK2, phospho-STAT3, STAT3, and Twist-1 proteins in 
Hs578T and MDA-MB-231 cells treated with 5 μM SU6656. β-actin was used as a loading control. B. Western blot analysis of expression 
of phospho-JAK2, JAK2, phospho-STAT3, STAT3, and Twist-1 proteins in Hs578T and MDA-MB-231 cells treated with 15 μM AG490. 
β-actin was used as a loading control. C. Identification of complex formation of endogenous TrkB/c-Src/JAK2 in MBA-MB-231 and 
Hs578T cells. D. Western blot analysis of whole-cell lysates and immunoprecipitates derived from 293T cells transfected with V5-TrkB, 
HA-c-Src and Myc-Jak2 constructs as indicated with or without 5 μM SU6656. E. The relative expression levels of mRNA encoding 
Twist-1 and Twist-2 in MDA-MB-231 cells stably expressing control shRNA or TrkB-shRNA treated with or without 5 μM SU6656, as 
determined by quantitative RT-PCR. F. Western blot analysis of the expression of phospho-JAK2, JAK2, phospho-STAT3, STAT3, and 
Twist-1 in SYF cells expressing either pCAG or pCAG/TrkB. β-actin was used as a loading control. G. Western blot analysis of expression 
of phospho-JAK2, JAK2, phospho-STAT3, STAT3, and Twist-1 in SYF cells or SYF-c-Src cells expressing either pCAG or pCAG/TrkB. 
β-actin was used as a loading control.
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constructs. A JAK2 mutant containing the tyrosine kinase 
domain interacted with TrkB, whereas TrkB did not interact 
with the JAK2 B41, SH2, or pseudokinase domain mutants 
(Supplementary Figure 2C). To further determine whether 
TrkB-JAK2 formed a complex in the absence of c-Src, we 
expressed TrkB in SYF cells derived from triple knock-
out mouse embryos lacking members of the Src kinase 
family (c-Src, Yes, and Fyn) (Klinghoffer et al., 1999). We 
transiently transfected SYF-TrkB and SYF-c-Src-TrkB cells 
with JAK2. As shown in Supplementary Figure 2D, TrkB-
JAK2 complexes were detected in both c-Src-deficient 
SYF-TrkB and SYF-c-Src-TrkB cells. Moreover, TrkB 
in the absence of c-Src was sufficient to induce of JAK2 
expression in SYF-TrkB cells (Supplementary Figure 2E).
Interestingly, MDA-MB-231 TrkB-shRNA cells 
demonstrated much lower Twist-1 and Twist-2 mRNA 
levels than MDA-MB-231 cells treated with SU6656 
(Figure 2E). Additionally, TrkB knockdown exhibited an 
almost 3-fold decrease in promoter activity of Twist-1 and 
Twist-2 genes relative to SU6656 treatment (Figures 2E and 
Supplementary 2F). These results suggest that Twist-1 or 
Twist-2 upregulation by TrkB might be regulated via at least 
two downstream pathways involving the c-Src. Moreover, 
TrkB-mediated JAK2 and STAT3 phosphorylation levels 
Figure 3: TrkB upregulates JAK2 expression by inhibiting the SOCS3-mediated degradation of JAK2. A. Western blot 
analysis of expression of phospho-JAK2, JAK2, phospho-STAT3, STAT3, and Twist-1 proteins in Hs578T and MDA-MB-231 control-
shRNA or TrkB-shRNA cells. β-actin was used as a loading control. B. Tyrosine kinase activity of TrkB is important to induction of 
the JAK2/STAT3 pathway. Western blot analysis of expression of phospho-JAK2, JAK2, phospho-STAT3, STAT3, and Twist-1 proteins 
in Hs578T and MDA-MB-231 cells treated with 50 nM K252a. C. The relative expression of JAK2 in Hs578T and MDA-MB-231 
control-shRNA or TrkB-shRNA cells, as determined by RT-PCR or western blotting. GAPDH and β-actin were used as loading controls. 
D. Western blot analysis of whole-cell lysates and immunoprecipitates derived from 293T cells transfected with the V5-TrkB, HA-Ubiquitin 
and  Myc-Jak2 constructs, as indicated. E. Western blot analysis of whole-cell lysates and immunoprecipitates derived from 293T cells 
transfected with the V5-TrkB, HA-Ubiquitin, Flag-SOCS3 and Myc-Jak2 constructs, as indicated. F. Western blot analysis of whole-cell 
lysates and immunoprecipitates derived from 293T cells transfected with the V5-TrkB, Flag-SOCS3, or Myc-Jak2 constructs as indicated. 
G. Endogenous TrkB inhibits SOCS3/JAK2 complex formation. The cell lysates were subjected to immunoprecipitation using anti-IgG and 
anti-JAK2 Abs followed by immunoblotting with anti-SOCS3, anti-JAK2, and anti-TrkB antibodies.
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were markedly increased in SYF-TrkB and SYF-cSrc-TrkB 
cells. Furthermore, JAK2, STAT3, and Twist-1 expression 
was markedly increased in SYF-TrkB or SYF-cSrc-TrkB 
cells compared to SYF or SYF-c-Src cells (Figure 2F and 
2G). These results were consistent with Twist-1 and Twist-2 
luciferase activity in SYF-TrkB and SYF-c-Src-TrkB cells. 
Also, ectopic TrkB expression increased promoter activity 
of Twist-1 and Twist-2 genes in SYF cells and SYF-c-
Src cells. Moreover, both TrkB and c-Src synergistically 
increased Twist-1 and Twist-2 luciferase activity 
(Supplementary Figure 2G), and significantly increased 
JAK2 and STAT3 expression, suggesting that TrkB directly 
activates JAK2 and STAT3 through upregulation of JAK2/
STAT3 expression with or without c-Src.
TrkB induces JAK2 stabilization through inhibition of 
its ubiquitination
We next attempted to investigate whether TrkB 
knockdown, which was identified above as being 
activated by the JAK2/STAT3/Twist-1 axis without 
c-Src, affects activation of the JAK2/STAT3/Twist-1 axis 
in Hs578T and MDA-MB-231 cells. Immunoblotting 
analysis revealed that JAK2 and STAT3 phosphorylation 
levels were markedly reduced in Hs578T and 
Figure 4: Induction of IL-6 secretion by TrkB enhances nuclear translocation of STAT3 and upregulates Twist-1 and 
Twist-2. A. The relative expression of mRNA encoding IL-6 in MDA-MB-231 cells relative to that of HMLE cells, as determined by 
quantitative RT-PCR. The 18S mRNA level was used to normalize the variability in template loading. B. The relative expression of the 
mRNA encoding IL-6 in MDA-MB-231 control-shRNA or TrkB-shRNA cells, as determined by quantitative RT-PCR. The 18S mRNA 
level was used to normalize the variability in template loading. C. IL-6 secretion by MDA-MB-231 control-shRNA or TrkB-shRNA cells, 
as determined by ELISA. The data are reported as the means ± SEM. D. Western blot analysis of the expression of phospho-JAK2, JAK2, 
phospho-STAT3, STAT3, and Twist-1 proteins in MDA-MB-231 and Hs578T control-shRNA or TrkB-shRNA cells treated with or without 
IL-6. β-actin was used as a loading control. E. Immunofluorescence images of STAT3 in MDA-MB-231 and Hs578T control-shRNA or 
TrkB-shRNA cells treated with IL-6. The green signal represents staining of the corresponding protein, while the blue signal represents 
DAPI staining. F. The relative expression levels of mRNA encoding Twist-1 and Twist-2 in MDA-MB-231 control-shRNA or TrkB-shRNA 
cells treated with IL-6, as determined by quantitative RT-PCR. The 18S mRNA level was used to normalize the variability in template 
loading. G. Promoter activity of Twist-1 and Twist-2 genes in MDA-MB-231 control-shRNA or TrkB-shRNA cells treated with or without 
IL-6. Each bar represents the mean ± SEM of three experiments.
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MDA-MB-231 TrkB-shRNA cells relative to its control-
shRNA cells. Interestingly, the JAK2, STAT3, and 
Twist expression levels were also significantly reduced 
in Hs578T and MDA-MB-231 TrkB-shRNA cells 
(Figure 3A). Additionally, STAT3, Twist-1 and Twist-2 
mRNA expression was markedly reduced in response to 
TrkB knockdown (Supplementary Figure 3A and 3C). 
Moreover, promoter activity of STAT3, Twist-1 and Twist-2 
genes was significantly decreased in Hs578T and MDA-
MB-231 TrkB-shRNA cells compared to its control-shRNA 
cells (Supplementary Figure 3B and 3D). Furthermore, 
the inhibition of TrkB activation by K252a treatment 
significantly reduced JAK2 and STAT3 phosphorylation 
and downregulated JAK2, STAT3, and Twist-1 expression 
(Figure 3B). These observations suggest that tyrosine kinase 
activity of TrkB is required for JAK2/STAT3/Twist-1 
induction as well as JAK2/STAT3 expression.
Because TrkB knockdown reduced the JAK2 protein 
levels, we initially focused on JAK2 expression. TrkB 
knockdown significantly reduced the JAK2 protein levels, 
but had no effect on JAK2 mRNA levels (Figure 3C), 
suggesting that TrkB post-translationally controls JAK2 
protein stability. The SOCS3 protein is known to bind 
to JAK2 and suppress JAK2 activity through direct 
binding to the JAK2 catalytic center and promotion of 
the proteasomal degradation of JAK2 [35]. Therefore, 
Figure 5: TrkB induces EMT program via upregulation of Twist-1 and Twist-2 expression. A. Western blot analysis of the 
expression of TrkB, E-cadherin, α-catenin, N-cadherin, and fibronetin proteins in MDCK, MCF10A, MDCK-TrkB, and MCF10A-TrkB 
cells. β-actin was used as a loading control. B. The relative expression levels of mRNA encoding E-cadherin, N-cadherin, vimentin, and 
fibronectin in MDCK, MCF10A, MDCK-TrkB, and MCF10A-TrkB cells, as determined by quantitative RT-PCR. The 18S mRNA level 
was used to normalize the variability in template loading. C. Promoter activity of E-cadherin gene in MDCK and MDCK-TrkB cells. 
Each bar represents the mean ± SEM of three experiments. D. Immunofluorescence images of E-cadherin and N-cadherin in MDCK, and 
MDCK-TrkB. The red signal represents staining of the corresponding protein, while the blue signal represents DAPI staining. E. Western 
blot analysis of the expression of Twist-1 protein (right) and RT-PCR analysis (left) of mRNA encoding Twist-2, E12, Goosecoid, SIP1, 
and Slug in MDCK, MCF10A, MDCK-TrkB, and MCF10A-TrkB cells. F. The relative expression levels of mRNA encoding Twist-1 and 
Twist-2 in MDCK, MCF10A, MCF10A-TrkB and MDCK-TrkB cells, as determined by quantitative RT-PCR. The 18S mRNA level was 
used to normalize the variability in template loading. G. Promoter activity of Twist-1 and Twist-2 genes in MDCK and MDCK-TrkB cells.
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we investigated whether JAK2 stabilization by TrkB was 
mediated through the suppression of JAK2 ubiquitination. 
When JAK2 was immunoprecipitated from the cell lysate, 
level of JAK2 ubiquitination was markedly reduced when 
TrkB was coexpressed (Figure 3D). TrkB also suppressed 
JAK2 ubiquitination, even in the presence of SOCS3, which 
mediated the negative feedback inhibition of the JAK–STAT 
pathway (Figure 3E). Therefore, we investigated whether 
TrkB induced JAK2 activation by blocking the ability of 
SOCS3 to ubiquitinate and degrade JAK2 through SOCS3-
JAK2 complex formation. As expected, TrkB coexpression 
significantly reduced the level of SOCS3-associated JAK2 
(Figure 3F). We next compared the JAK2-SOCS3 complex 
formation in MDA-MB-231 and Hs578T TrkB-shRNA cells 
to that of the control-shRNA cells. The level of endogenous 
SOCS3 associated with JAK2 was dramatically increased in 
MDA-MB-231 and Hs578T TrkB-shRNA cells, which was 
correlated with decreased JAK2 (Figure 3G). These results 
indicated that TrkB inhibited proteasome-mediated JAK2 
degradation by blocking SOCS3-JAK2 complex formation, 
leading to activation of the JAK2/STAT3/Twist-1 axis.
Increased secretion of IL-6 protein by TrkB 
increases the nuclear translocation of STAT3
STAT3 phosphorylation by IL-6 promotes its 
nuclear translocation and DNA binding followed by the 
transactivation of genes involved in a number of cellular 
Figure 6: Suppression of TrkB expression inhibited metastasis from the mammary gland to the lung. A, B. Tumor formation 
by MDA-MB-231 control-shRNA or MDA-MB-231 TrkB-shRNA cells. 1.0 × 105 cells were implanted in the mammary fat pads of mice (n 
= 7 mice/group). A P < 0.0001 was considered to indicate significance for ANOVA. C. Lung metastasis by MDA-MB-231 control-shRNA 
or MDA-MB-231 TrkB-shRNA cells. The total numbers of lung metastatic nodules in each mouse in each group were counted using a 
dissection scope (n = 6 mice/group). A P < 0.0001 was considered to indicate significance for ANOVA. D. Representative images of lungs 
from mice harboring MDA-MB-231 control-shRNA or TrkB-shRNA cell mammary tumors for 30 days after implantation of tail veins of mice. 
E. Representative H&E staining in sections of the lungs from Figure 6D. N, Normal lung tissue; M, metastatic nodule. F, G. Western blot 
analysis (F) and quantitative RT-PCR (G) of TrkB, and Twist-1 in tumor cells recovered from the lungs of individual mice expressing either 
MDA-MB-231 control-shRNA or MDA-MB-231 TrkB-shRNA. Tubulin and 18S mRNA were used as loading controls. H. Representative 
immunohistochemical images of Twist-1 staining in sections of the lungs from individual mice expressing either MDA-MB-231 control-
shRNA or MDA-MB-231 TrkB-shRNA (magnification: 200×). I. The expression levels of the mRNA encoding Twist-1 and Twist-2 in tumor 
cells recovered from the lungs of individual mice expressing either MDA-MB-231 control-shRNA or TrkB-shRNA cells.
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functions, including proliferation, differentiation, and 
survival (Catlett-Falcone et al., 1999; Heinrich et al., 2003; 
Oshiro et al., 2001; Puthier et al., 1999). Moreover, the IL-6/
STAT3/JAK2 pathway is involved in the maintenance of 
stem cell–like cancer cells [36] because CD44+CD24+ and 
CD44+CD24- breast cancer cells have high phospho-STAT3 
via their expression of genes such as IL6, PTGIS, and HAS1, 
which activate an autocrine loop [8]. Furthermore, high 
IL-6 levels have been associated with poor clinical outcome 
in breast cancer patients [37]. We speculated that STAT3 
activation by TrkB depends on the activation of autocrine 
signaling loops. To investigate whether TrkB is relevant to 
IL-6 expression, we examined IL-6 expression in a panel of 
HMLE and MDA-MB-231 or its TrkB knockdown cells. 
The mRNA levels of IL-6 were significantly upregulated 
in MDA-MB-231 cells relative to HMLE and its TrkB 
knockdown cells (Figure 4A and 4B). Together, increased 
secretion of IL-6 protein (4.5- to 5-fold) by MDA-MB-231 
cells, relative to TrkB knockdown cells, correlated with 
increased mRNA levels of IL-6 (Figure 4C).
To further examine the TrkB-mediated regulation 
of the JAK2/STAT3 pathway, we assessed IL-6-induced 
JAK2 and STAT3 activation in MBA-MB-231 and Hs578T 
control-shRNA or TrkB-shRNA cells. Relative to the MDA-
MB-231 and Hs578T control-shRNA cells, TrkB-shRNA 
cells showed significantly reduced activation and expression 
of JAK2/STAT3, as well as Twist-1 expression after 
stimulation with or without IL-6 (Figure 4D). Furthermore, 
STAT3 nuclear translocation after IL-6 treatment was 
markedly increased in MDA-MB-231 and Hs578T control-
shRNA cells relative to TrkB knockdown cells (Figure 
4E). Additionally, the expression and promoter activity 
of Twist-1 and Twist-2 genes was markedly increased in 
MDA-MB-231 and Hs578T control-shRNA cells, but not in 
its TrkB-shRNA cells (Figure 4F and 4G). Together, these 
observations indicate that the role of TrkB in activation of 
the IL6/JAK2/STAT3 pathway can also serve to induce 
entry into a stem cell-like state, allowing the derivation of 
cells with metastatic potential.
TrkB induces EMT through activation of the 
JAK2/STAT3 pathway and PI3K/AKT pathway
The results of a recent study suggests that Twist-1 and 
Twist-2 induce activation of the EMT program to maintain 
the resulting mesenchymal state [38–40]. Moreover, 
cooperation between the Stat3 and AKT signaling 
pathways results in tumor development and EMT in the 
prostates of mice [11]. Therefore, we investigated whether 
the contribution of TrkB to tumor metastasis involved 
EMT induction through activation of the JAK2/STAT3 
and PI3K/AKT pathways. To address this possibility, we 
examined whether expression of TrkB was able to promote 
an EMT in normal mammalian cells. To accomplish this, 
we overexpressed TrkB in MDCK and MCF10A cells by 
ectopic expression of TrkB. As anticipated, MDCK-TrkB 
and MCF10A-TrkB cells downregulated the expression 
of mRNA and proteins of epithelial markers (such as 
E-cadherin, and α-catenin), while they upregulated the 
expression of mRNA and proteins of mesenchymal 
markers (such as N-cadherin, fibronectin, and vimentin) 
(Figure 5A and 5B). Also, promoter activity of E-cadherin 
gene was also efficiently suppressed in the MDCK-TrkB 
cells compared to the MDCK-control cells (Figure 5C). 
In addition, immunostaining revealed that, relative to the 
expression of E-cadherin in MDCK-TrkB cells, the level 
of E-cadherin in MDCK cells was strongly induced and 
N-cadherin expression was markedly reduced (Figure 5D).
During the process of tumor metastasis, which is 
often enabled by EMT program, pleiotropically acting 
transcription factors, such as E12, Goosecoid, SIP1, 
Snail, Twist-1, and Twist-2, are induced that orchestrate 
EMT programs [6, 41]. These recent study and our above 
observations led us to speculate that TrkB might contribute 
to induction of EMT via modulation of pleiotropically 
acting transcription factors. We examined whether 
TrkB regulates the expression of SIP1, E12, Goosecoid, 
Twist-1, and Twist-2. There was a considerable increase 
in the expression of EMT-inducing transcription factors, 
specifically Twist-1, and Twist-2, in MDCK-TrkB 
and MCF10A-TrkB cells but not with SIP1, E12, and 
Goosecoid expression (Figure 5E), which was correlated 
with increased luciferase activity and expression of mRNA 
encoding Twist-1 and Twist-2 (Figure 5F and 5G).
Also, relative to the parental MDA-MB-231 
control-shRNA cells, TrkB-shRNA cells significantly 
downregulated the expression of mesenchymal markers such 
as N-cadherin and fibronectin, whereas they upregulated the 
expression of epithelial markers (such as E-cadherin and 
α-catenin). Moreover, the levels of Twist-1 was significantly 
downregulated in MDA-MB-231 TrkB-shRNA cells relative 
to MDA-MB-231 control-shRNA cells (Supplementary 
Figure 4A). Furthermore, we found that the immunoactivity 
of epithelial or mesenchymal markers in MDA-MB-231 
control-shRNA cells was correlated with the expression levels 
of MDCK-TrkB cells as shown in Supplementary Figure 4B. 
In addition, immunostaining data revealed that the Twist-1 
protein in MDA-MB-231 control-shRNA cells was strongly 
upregulated (Supplementary Figure 4C) relative to the 
expression of Twist-1 in MDA-MB-231 TrkB-shRNA cells, 
which was correlated with the expression of mRNA encoding 
Twist-1 and Twist-2. These results provided further evidence 
that TrkB contributed to the EMT phenotype through 
activation of the PI3K/AKT and IL6/JAK2/STAT3 pathway.
Knockdown of TrkB significantly reduces tumor 
growth and metastasis in vivo
To determine the contribution of TrkB to primary 
tumor formation, we injected MDA-MB-231 cells 
expressing either TrkB-shRNA or control-shRNA into 
the mouse mammary fat pads of BALB/c Nu/Nu mice 
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and examined the resulting primary tumors 30 days later. 
Control MDA-MB-231 cells formed primary mammary 
tumors at identical rates, whereas primary tumor formation 
by MDA-MB-231 TrkB-shRNA cells was markedly 
decreased (Figure 6A and 6B). These results demonstrate 
that TrkB is essential to primary tumor formation by 
MDA-MB-231 cells.
To determine if the loss of TrkB expression affected 
the ability of MDA-MB-231 cells to metastasize, MDA-
MB-231 cells expressing either TrkB-shRNA or the control 
shRNA were injected into the tail veins of BALB/c Nu/Nu 
mice, and their lungs were examined for metastases 35 days 
after injection. Suppression of TrkB expression strongly 
reduced the number of metastatic nodules relative to 
MDA-MB-231 control-shRNA cells (Figure 6C and 6D). 
Additionally, histological analyses confirmed that the 
number of micrometastatic lesions was drastically reduced 
in the lungs of mice with MDA-MB-231 TrkB-shRNA cells 
(Figure 6E). Importantly, few metastatic nodules in the 
lungs of mice carrying TrkB-shRNA cells retained TrkB 
expression, but TrkB expression in the lungs of mice with 
TrkB-shRNA cells was greatly reduced relative to the lungs 
of mice carrying control-shRNA cells (Figure 6F and 6G). 
Moreover, quantitative RT-PCR and immunohistochemistry 
analysis of Twist-1 and Twist-2 revealed reduced expression 
in the lungs of mice injected with MDA-MB-231 TrkB-
shRNA cells compared to their control counterparts (Figure 
6H and 6I). These results indicated that expression of TrkB 
is required for the full metastatic ability of highly metastatic 
MDA-MB-231 breast cancer cells.
DISCUSSION
TrkB is overexpressed in several human cancers, 
ranging from neuroblastomas to pancreatic ductal 
adenocarcinomas, and its overexpression suppresses 
anoikis as an EMT inducer by regulation of Zeb1 [23, 42]. 
Independent of these discoveries, CD44high/CD24low cells, 
which show a stem cell-like phenotype, are enriched in 
highly metastatic breast cancer cells (basal or claudin-low 
breast subtypes) have been proposed to be resistant to cancer 
therapies through activation of the PI3K/AKT pathway, 
IL-6/JAK2/STAT3 pathway, and EMT [8, 43–47]. Although 
increasing evidence implies that altered PI3K/AKT signaling 
in response to ectopic TrkB promotes tumor formation and 
metastasis, the molecular mechanisms of TrkB-mediated 
PI3K/AKT modulation in breast cancer have remained 
unknown, and none of the findings reported to date hinted at 
a link between these two sets of phenomena.
In the present study, we found that activation of the 
MEK and PI3K/AKT pathway through TrkB-mediated 
c-Src activation after TrkB-c-Src complex formation 
induced tumorigenicity and metastatic potential of breast 
cancer. These our results are supported by those of a 
previous study in which the phosphatidylinositol-3-OH 
kinase/protein kinase B signaling pathways required for 
EMT, anokis suppression, c-Src activated PI3K/AKT and 
Ras/MAPK cascades [23, 27, 48, 49].
We further dissected the role of TrkB in 
tumorigenicity and metastasis. Activated STAT3 was 
able to transform cells in vitro and was required for cell 
transformation of a number of oncogenes and activation 
of STAT3 by interleukin-6 or expression of activated c-Src 
induced Twist expression at the protein and mRNA levels 
[29–31, 34, 50–52]. These previous observations led us to 
investigate whether TrkB regulates STAT3 activation via 
c-Src activation. We found that c-Src activation by TrkB 
was required for JAK2 activation through interaction with 
JAK2, but not with STAT3. TrkB significantly upregulated 
the JAK2 protein level, which had no effect on the JAK2 
mRNA level. Moreover, TrkB in the absence of c-Src 
is sufficient to activate JAK2/STAT3 through blocking 
of JAK2 degradation by SOCS3 after directly binding 
to the JAK2, as well as upregulation of EMT related 
transcription factors, such as Twist-1 and Twist-2. A 
great deal of research has described the role of SOCS3, 
which specifically prevents activation of STAT3 by IL-6 
[35, 53–57]. Our studies further uncovered TrkB as a key 
regulator in coordinating the actions of JAK2 and c-Src in 
tumorigenesis.
Recent studies showed that the IL-6 inflammatory 
feedback loop leads to CSC self-renewal and induction of 
EMT, both of which are implicated in tumor metastasis and 
poor outcomes by therapeutic resistance [8, 9, 36, 37, 58]. 
Moreover, IL-6 secretion induced by HER2 overexpression 
elicited JAK2/STAT3 activation [59]. Therefore, we 
investigated whether TrkB enforces an autocrine loop 
of IL-6/JAK2/STAT3 via induction of IL-6 secretion. 
Although IL-6 is regulated by multiple factors, increased 
secretion of IL-6 protein (4.5- to 5-fold) by TrkB was 
found to be correlated with increased mRNA levels of IL-
6. Furthermore, induction of STAT3 nuclear translocation 
by TrkB induced EMT via increased expression of EMT 
related transcription factors such as Twist-1 and Twist-2.
Recent evidence indicates transcription factors Twist-1 
and Twist-2, which are master regulators of embryonic 
morphogenesis, play an essential role in metastasis, CSCs 
and EMT of breast cancer [39, 40, 60–66]. Both proteins 
override oncogene induced premature senescence by 
abrogating key regulators of the p53- and Rb-dependent 
pathways. Moreover, AKT2 is a transcriptional regulatory 
target of Twist that acts downstream of Twist to promote 
cancer cell survival, migration, and invasion [67]. In 
addition, JAK2/STAT3 activity is required for activation of 
the PI3K/AKT pathway via upregulation of AKT1 promoter 
activity [10, 68]. Those studies and our results presented 
herein indicate that downstream mediation of TrkB is more 
complex, and is likely to be cellular context dependent and/
or promoter dependent. Although the results of this study by 
no means exclude the involvement of other factors, they do 
suggest that activation of the IL-6 autocrine loop by TrkB 
maintains the metastatic potential and CSCs self-renewal 
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via activation of the JAK2/STAT3 pathway, PI3K/AKT 
pathway, and EMT (Supplementary Figure 5). Overall, we 
identified a new molecular and functional network present in 
cancer metastasis that regulates and coordinates with TrkB. 
Moreover, we demonstrated that TrkB has the potential for 
use as a new target for improving the treatment efficacy of 
metastatic breast cancer.
MATERIALS AND METHODS
Cell culture and reagents
Human breast cancer (MCF10A, SUM149, MDA-
MB-231, and Hs578T), SYF, 293T, and MDCK cell lines 
were maintained as previously described [40, 69, 70]. The 
protein kinase inhibitor K252a and SU6656, and AG490 
was purchased from Calbiochem.
Plasmids
Each of the two shRNA-encoding oligonucleotides 
against mouse and human TrkB was designed and verified 
to be specific to TrkB through BLAST searches against 
the mouse and human genomes, respectively. The primers 
corresponding to TrkB were cloned into the pLKO lentiviral 
vector to generate the TrkB-shRNA expression plasmid 
(Supplementary Table 1). shRNA that did not match any 
known mouse- or human-coding cDNA was used as a control.
Antibodies, western blotting, 
immunoprecipitation, and immunofluorescence
Assays were performed as previously described, 
with modification [40, 69]. The antibodies were obtained 
from the following companies: anti-HA(Y-11), anti-c-Src, 
and anti-Myc (9E10) were from Santa Cruz; anti-V5 was 
from Invitrogen; anti-TrkB and anti-SOCS3 were from 
Abcam; anti-phospho-c-Src, anti-Twist-1, anti-STAT3, 
anti-phospho-STAT3, anti-JAK2, and anti-phospho-
JAK2 were from Cell Signaling Technology; and anti-E-
cadherin, anti-fibronectin, anti-N-cadherin, anti-α-catenin, 
and anti-β-catenin were from BD Transduction.
Viral production, colony formation assay, and 
RT-PCR
All assays were performed as previously described 
[69, 71]. The primer sequences used to amplify the genes are 
listed in the Supplementary Tables (Supplementary Table 2).
Quantitative RT-PCR
The primer sequences are listed in the supplemental 
experimental procedures (Supplementary Table 2). Total 
RNA was isolated using RNeasy Mini Kits (Qiagen) 
according to the manufacturer’s instructions and reverse 
transcribed with the hexa-nucleotide mix (Roche). The 
resulting cDNA was employed in PCR using SYBR-
Green Master PCR mix and Taqman master PCR mix 
(Applied Biosystems). All PCR analyses were conducted 
in triplicate using the 7900HT Fast Real-Time PCR 
System (Applied Biosystems). All quantitations were 
normalized to endogenous control 18S RNA. Specific 
TrkB (Hs00178811_m1) and 18S (Hs99999901_s1) 
quantitative probes for Taqman RT-PCR were obtained 
from Applied Biosystems and the primer sequences used 
to amplify the genes are listed in Supplementary Table 2.
Luciferase reporter assay
Cells that were 50% confluent in 12-well dishes 
were transfected using Lipofectamine 2000 (Invitrogen). 
A total of 0.5 μg E-cadherin, Twist-1, Twist-2, or STAT3 
reporter gene constructs and 0.5 μg of pCMV-β-gal were 
cotransfected per well. Cell extracts were prepared 48 hrs 
after transfection, and the luciferase activity was quantified 
using an Enhanced Luciferase Assay Kit (Promega). All 
experiments were performed in triplicate.
Animal studies
BALB/c Nu/Nu mice were purchased from the 
Korea Research Institute of Bioscience and Biotechnology 
(KRIBB, South Korea) and handled in compliance with the 
IACUC. For tumorigenicity studies, 1 × 105 cells suspended 
in 50 μl PBS/Matrigel (BD Biosciences) were injected 
subcutaneously into the left and right hind flank regions under 
anesthesia. Mice were euthanized at 5 weeks and primary 
tumors were excised for analysis. For tail-vein injection, 1 × 
105 cells suspended in 50 μl PBS were injected into the tail 
vein of 7-week-old BALB/c Nu/Nu mice.
In vivo bioluminescent imaging
Mice were given intraperitoneal injections of 150 
ng/g D-Luciferin (Caliper Life Sciences, cat#12279) 
and anesthetized with 2.5% isoflurane. At 7–8 min after 
injection, animals were imaged using the Xenogen 
Spectrum (IVIS-200) imaging system.
IL-6 ELISA assay
The equal numbers of MDA-MB-231 control-
shRNA or TrkB-shRNA cells were plated and cultured for 
3 days. Subsequently, conditioned media from these cell 
cultures were collected and analyzed by the Human IL-6 
Quantikine ELIZA kit (R&D systems) according to the 
manufacturer’s instructions.
Statistical analysis
Data are expressed as the means ± SEM. Statistical 
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